Received Apr 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 75GZ7 | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
received third dose of Shingrix; 2nd dose administered on 31 January 2025; This non-serious case was reported by a other health professional via sales rep and described the occurrence of extra dose administered in a 56-year-old female patient who received Herpes zoster (Shingrix) (batch number 75GZ7) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose received on 04th April 2019). Concurrent medical conditions included diabetes. Concomitant products included metformin hydrochloride (Metformin). On 07-APR-2025, the patient received the 3rd dose of Shingrix. On 31-JAN-2025, the patient received the 2nd dose of Shingrix. On 31-JAN-2025, not applicable after receiving Shingrix and an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: 2nd dose administered on 31 January 2025). On 07-APR-2025, the patient experienced extra dose administered (Verbatim: received third dose of Shingrix). The outcome of the extra dose administered and drug dose administration interval too long were not applicable. Additional Information: GSK receipt date: 14-APR-2025 The patient took 3 doses of Shingrix. The first one was administered on 04th April 2019 and the second dose on 31st January 2025 which led to drug dose administration interval too long. The third dose of vaccine was administered on 07th April 2025 which led to extra dose administration.
Diabetes
Metformin